AstraZeneca plc vs Open Text Corporation — how do they compare? AstraZeneca plc trades at $166.7 (market cap $253.13B), while Open Text Corporation trades at $22.53 (market cap $5.40B). The key difference: AstraZeneca plc is far larger — about 46.9× Open Text Corporation's market cap, and Open Text Corporation pays the higher dividend (4.9%). Which is the better fit depends on your goals.
| AZN | OTEX | |
|---|---|---|
Market Cap | $253.13B | $5.40B |
Sector | Health | Technology |
52-Week High | $209.48 | $39.69 |
52-Week Low | $137.44 | $20.01 |
Enterprise Value | $279.37B | $10.56B |
Dividend Yield | 1.92% | 4.9% |
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
OpenText (OTEX) trades at $23.57, up 2.43% on the day, with a bullish technical signal from moving averages. The company shows strong profitability with a 73.06% gross margin and has beaten earnings estimates for the last three quarters. Recent strategic moves include a $105 million investment in European AI and cloud expansion and the divestiture of the non-core Vertica business.
The outlook is positive, supported by a consensus analyst price target of $29.75, implying significant upside. Key opportunities include margin expansion and AI-driven growth, while risks involve integration of strategic shifts and competitive pressures in the enterprise software market.
Trailing returns across standard periods
Latest headlines on both assets
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →